[go: up one dir, main page]

AR099289A1 - Proteínas de fusión de interleucina-2 y usos de las mismas - Google Patents

Proteínas de fusión de interleucina-2 y usos de las mismas

Info

Publication number
AR099289A1
AR099289A1 ARP150100325A ARP150100325A AR099289A1 AR 099289 A1 AR099289 A1 AR 099289A1 AR P150100325 A ARP150100325 A AR P150100325A AR P150100325 A ARP150100325 A AR P150100325A AR 099289 A1 AR099289 A1 AR 099289A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
refers
interleucine
same
treatment
Prior art date
Application number
ARP150100325A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR099289A1 publication Critical patent/AR099289A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere generalmente a proteínas de fusión de inmunoglobulinas e interleucina-2 (IL-2). Más particularmente, se refiere a proteínas de fusión de inmunoglobulinas e IL-2 mutante que muestra propiedades mejoradas para su uso como agentes terapéuticos, por ejemplo, en el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias mediadas por el sistema inmune. Además, la presente se refiere a polinucleótidos que codifican dichas proteínas de fusión, y a vectores y células hospedadoras que comprenden dichos polinucleótidos. Se refiere además a métodos para producir las proteínas de fusión y a métodos de uso en el tratamiento de enfermedades. Composición farmacéutica.
ARP150100325A 2014-02-06 2015-02-05 Proteínas de fusión de interleucina-2 y usos de las mismas AR099289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461936564P 2014-02-06 2014-02-06

Publications (1)

Publication Number Publication Date
AR099289A1 true AR099289A1 (es) 2016-07-13

Family

ID=52669578

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100325A AR099289A1 (es) 2014-02-06 2015-02-05 Proteínas de fusión de interleucina-2 y usos de las mismas

Country Status (32)

Country Link
US (1) US11098099B2 (es)
EP (2) EP3508496A1 (es)
JP (2) JP6306201B2 (es)
KR (2) KR20190126205A (es)
CN (2) CN111423513A (es)
AR (1) AR099289A1 (es)
AU (2) AU2015215001B2 (es)
BR (1) BR112016018288A2 (es)
CA (1) CA2931114A1 (es)
CL (1) CL2016001968A1 (es)
CR (1) CR20160333A (es)
DK (1) DK3102595T3 (es)
EA (2) EA034350B1 (es)
ES (1) ES2704731T3 (es)
HR (1) HRP20190028T1 (es)
HU (1) HUE041530T2 (es)
IL (1) IL245484B (es)
LT (1) LT3102595T (es)
MA (1) MA39250B1 (es)
MX (2) MX370283B (es)
NZ (2) NZ719654A (es)
PE (1) PE20161324A1 (es)
PH (1) PH12016501406B1 (es)
PL (1) PL3102595T3 (es)
PT (1) PT3102595T (es)
RS (1) RS58149B1 (es)
SG (1) SG11201606369XA (es)
SI (1) SI3102595T1 (es)
TW (1) TWI671318B (es)
UA (1) UA120847C2 (es)
WO (1) WO2015118016A1 (es)
ZA (1) ZA201603262B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
BR112018010937A2 (pt) 2015-12-04 2018-12-04 Novartis Ag composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
EP3919065B9 (en) 2016-01-14 2024-01-24 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
EP3529350A1 (en) 2016-10-19 2019-08-28 H. Hoffnabb-La Roche Ag Method for producing an immunoconjugate
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
CA3044416A1 (en) * 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3746103A4 (en) * 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
CA3102829A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
AU2019343251B2 (en) 2018-09-21 2022-06-09 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin 2 and use thereof
US20220089667A1 (en) * 2019-01-07 2022-03-24 Inhibrx, Inc. Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
IL286711B2 (en) * 2019-03-29 2025-10-01 Inst Curie Interleukin 2 variants with different biological activities
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
KR20220035122A (ko) * 2019-06-14 2022-03-21 큐진 인크. 신규한 인터루킨-2 변이체 및 이의 이작용성 융합 분자
WO2021011353A1 (en) * 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
MX2022007754A (es) * 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
IL295143B1 (en) 2020-02-13 2025-10-01 Hoffmann La Roche A method for determining the loading state of AAV particles using nuclear magnetic resonance relaxometry
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
WO2022050401A2 (en) * 2020-09-01 2022-03-10 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
CN116635403A (zh) * 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
WO2022179970A1 (en) 2021-02-24 2022-09-01 F. Hoffmann-La Roche Ag Regeneration and multiple use of depth filters
CN115232215A (zh) * 2021-04-23 2022-10-25 北京大学 一种融合蛋白ABD/Fc/IL-2及其编码基因、制备方法和应用
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
CN118414160A (zh) * 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
CA3265946A1 (en) 2022-09-12 2024-03-21 Sorbonne Universite INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
CA2320403A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CA2557677A1 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
HRP20130440T1 (en) 2004-04-13 2013-06-30 F. Hoffmann - La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20060110398A1 (en) 2004-11-24 2006-05-25 Schering Corporation DAP-10 and uses thereof
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
MA34519B1 (fr) 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
ES2693645T3 (es) 2011-03-11 2018-12-13 Assistance Publique - Hôpitaux De Paris Uso de IL-2 a baja dosis para tratar la diabetes tipo 1
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3626739A1 (en) * 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
PH12016501406A1 (en) 2016-08-31
US20150218260A1 (en) 2015-08-06
CA2931114A1 (en) 2015-08-13
EP3508496A1 (en) 2019-07-10
EP3102595A1 (en) 2016-12-14
IL245484A0 (en) 2016-06-30
NZ719654A (en) 2020-06-26
UA120847C2 (uk) 2020-02-25
KR20160103134A (ko) 2016-08-31
ES2704731T3 (es) 2019-03-19
MX2019014695A (es) 2020-02-07
PH12016501406B1 (en) 2022-04-22
ZA201603262B (en) 2019-10-30
JP6306201B2 (ja) 2018-04-04
AU2015215001B2 (en) 2019-08-15
LT3102595T (lt) 2019-01-25
EA034350B1 (ru) 2020-01-30
CR20160333A (es) 2016-09-05
RS58149B1 (sr) 2019-02-28
KR102042246B1 (ko) 2019-11-28
MX2016009687A (es) 2017-03-10
SI3102595T1 (sl) 2019-02-28
TWI671318B (zh) 2019-09-11
US11098099B2 (en) 2021-08-24
TW201534625A (zh) 2015-09-16
MX370283B (es) 2019-12-09
JP2018102312A (ja) 2018-07-05
IL245484B (en) 2019-10-31
WO2015118016A1 (en) 2015-08-13
CN105980410A (zh) 2016-09-28
HUE041530T2 (hu) 2019-05-28
PE20161324A1 (es) 2016-11-25
KR20190126205A (ko) 2019-11-08
PT3102595T (pt) 2019-01-11
HRP20190028T1 (hr) 2019-02-22
MA39250B1 (fr) 2018-09-28
MA39250A1 (fr) 2018-03-30
PL3102595T3 (pl) 2019-04-30
BR112016018288A2 (pt) 2017-10-10
CL2016001968A1 (es) 2017-02-24
EP3102595B1 (en) 2018-11-07
JP2017510551A (ja) 2017-04-13
SG11201606369XA (en) 2016-09-29
CN105980410B (zh) 2020-02-28
EA201992609A1 (ru) 2020-03-04
CN111423513A (zh) 2020-07-17
NZ760289A (en) 2023-05-26
AU2015215001A1 (en) 2016-05-19
DK3102595T3 (en) 2019-02-04
AU2019264579A1 (en) 2019-12-05
EA201691576A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
PE20150752A1 (es) Proteinas de fusion de interleuquina-2 y usos de las mismas
UY36021A (es) Proteìnas fc multimèricas
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
BR112017018975A2 (pt) proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
MX2016009809A (es) Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
ECSP18041733A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación
PH12017501522A1 (en) Antibodies to tau and uses thereof
MX2016010953A (es) Proteinas de fc multimericas.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
CL2015002620A1 (es) Derivados piridin-4-ilo
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure